| scholarly article | Q13442814 |
| P50 | author | Nahum Sonenberg | Q904654 |
| Gianluigi Condorelli | Q37839035 | ||
| Daniele Catalucci | Q53518460 | ||
| Marcello Ceci | Q58881311 | ||
| P2093 | author name string | Kirk L Peterson | |
| Kun-Liang Guan | |||
| Shigeki Miyamoto | |||
| Roberto Rizzi | |||
| Ju Chen | |||
| Nancy D Dalton | |||
| Yusu Gu | |||
| Joan Heller Brown | |||
| Jianlin Zhang | |||
| Katherine Huang | |||
| Michael V G Latronico | |||
| Riccardo Contu | |||
| Denghong Zhang | |||
| P2860 | cites work | Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 |
| PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex | Q24316314 | ||
| mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1 | Q24319851 | ||
| Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling | Q24323370 | ||
| mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) | Q24324148 | ||
| Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression | Q24554226 | ||
| Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development | Q24563399 | ||
| mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells | Q24564276 | ||
| Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism | Q24603034 | ||
| The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease | Q24606673 | ||
| TOR signaling in growth and metabolism | Q27860757 | ||
| Regulation of translation initiation in eukaryotes: mechanisms and biological targets | Q28111696 | ||
| Selective requirement of myosin light chain 2v in embryonic heart function | Q28258434 | ||
| Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1 | Q28276788 | ||
| Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB | Q28306356 | ||
| The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C | Q28587901 | ||
| Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies | Q28590387 | ||
| Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity | Q29614241 | ||
| MicroRNA-133 controls cardiac hypertrophy | Q29616572 | ||
| mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex | Q29617214 | ||
| Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy | Q33589972 | ||
| Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice | Q34156036 | ||
| Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency | Q34277370 | ||
| MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure | Q34416947 | ||
| Cardiac plasticity | Q34764732 | ||
| Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy | Q34891582 | ||
| mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex | Q34998143 | ||
| Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy | Q35126646 | ||
| Hypertrophy of the heart: a new therapeutic target? | Q35739349 | ||
| Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function | Q36646353 | ||
| Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin | Q37110578 | ||
| Akt regulates L-type Ca2+ channel activity by modulating Cavalpha1 protein stability. | Q37234352 | ||
| The role of autophagy in the heart. | Q37325466 | ||
| Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. | Q37376549 | ||
| Targeting mTOR with rapamycin: one dose does not fit all | Q37409171 | ||
| Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction | Q37467718 | ||
| Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy | Q37596176 | ||
| TOR complex 2: a signaling pathway of its own. | Q37624179 | ||
| Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway | Q41884318 | ||
| Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. | Q42511063 | ||
| Cell biology. Burn out or fade away? | Q43142725 | ||
| Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction | Q43190981 | ||
| Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein | Q43664631 | ||
| ErbB2 is essential in the prevention of dilated cardiomyopathy. | Q43976647 | ||
| Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes | Q44201590 | ||
| Rapamycin attenuates load-induced cardiac hypertrophy in mice | Q44385669 | ||
| Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload | Q44927100 | ||
| Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. | Q45022812 | ||
| Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty | Q45863592 | ||
| Transthoracic echocardiography in models of cardiac disease in the mouse. | Q45963321 | ||
| Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial | Q46514014 | ||
| Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy | Q46946750 | ||
| High-efficiency CAG-FLPe deleter mice in C57BL/6J background. | Q48558901 | ||
| Effects of protein phosphorylation on ubiquitination and stability of the translational inhibitor protein 4E-BP1. | Q53538416 | ||
| Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase | Q73554710 | ||
| New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material | Q77925507 | ||
| Cardiac-specific overexpression of E40K active Akt prevents pressure overload-induced heart failure in mice by increasing angiogenesis and reducing apoptosis | Q79610474 | ||
| Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis | Q80027046 | ||
| Akt1 is required for physiological cardiac growth | Q83195147 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2805-2816 | |
| P577 | publication date | 2010-07-19 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. | |
| P478 | volume | 120 |
| Q28546463 | 17ß-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling |
| Q26767331 | 5'-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complications |
| Q42116782 | A novel insight into the cardiotoxicity of antineoplastic drug doxorubicin. |
| Q28570967 | A-kinase anchoring protein Lbc coordinates a p38 activating signaling complex controlling compensatory cardiac hypertrophy |
| Q36700031 | AMPK attenuates microtubule proliferation in cardiac hypertrophy |
| Q90735566 | ATF6 Regulates Cardiac Hypertrophy by Transcriptional Induction of the mTORC1 Activator, Rheb |
| Q39285312 | Ablation of ALCAT1 mitigates hypertrophic cardiomyopathy through effects on oxidative stress and mitophagy |
| Q35789287 | Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities |
| Q64374807 | Adenosine kinase attenuates cardiomyocyte microtubule stabilization and protects against pressure overload-induced hypertrophy and LV dysfunction |
| Q54373272 | Akt-mTOR Pathway Inhibits Apoptosis and Fibrosis in Doxorubicin-Induced Cardiotoxicity Following Embryonic Stem Cell Transplantation. |
| Q28535743 | Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade |
| Q41880723 | Arrest of myelination and reduced axon growth when Schwann cells lack mTOR. |
| Q56975424 | Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes |
| Q27692538 | Autophagy and cardiovascular aging: lesson learned from rapamycin |
| Q38837178 | Autophagy in cardiac metabolic control: Novel mechanisms for cardiovascular disorders |
| Q37999635 | Autophagy, myocardial protection, and the metabolic syndrome. |
| Q42042549 | Blockade of the acute activation of mTOR complex 1 decreases hypertrophy development in rats with severe aortic valve regurgitation |
| Q64244738 | Blossoming 20: The Energetic Regulator's Birthday Unveils its Versatility in Cardiac Diseases |
| Q34808547 | Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? |
| Q96586585 | CYLD exaggerates pressure overload-induced cardiomyopathy via suppressing autolysosome efflux in cardiomyocytes |
| Q36061754 | Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart |
| Q52727269 | Cardiac Arrhythmias and Antiarrhythmic Drugs: An Autophagic Perspective. |
| Q37179335 | Cardiac Gab1 deletion leads to dilated cardiomyopathy associated with mitochondrial damage and cardiomyocyte apoptosis |
| Q36791996 | Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling |
| Q37421014 | Cardiac ablation of Rheb1 induces impaired heart growth, endoplasmic reticulum-associated apoptosis and heart failure in infant mice |
| Q35251097 | Cardiac insulin resistance and microRNA modulators |
| Q40284379 | Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy |
| Q36115340 | Cardiac mTOR protects the heart against ischemia-reperfusion injury |
| Q52309831 | Cardiac mTORC1 Dysregulation Impacts Stress Adaptation and Survival in Huntington's Disease. |
| Q35657122 | Cardiomyocyte death: mechanisms and translational implications |
| Q58791389 | Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action |
| Q38130112 | Cardiovascular autophagy: concepts, controversies, and perspectives |
| Q36062316 | Cardiovascular disease and mTOR signaling |
| Q36842427 | Chronic Akt activation attenuated lipopolysaccharide-induced cardiac dysfunction via Akt/GSK3β-dependent inhibition of apoptosis and ER stress |
| Q40842721 | Clinical impact of myocardial mTORC1 activation in nonischemic dilated cardiomyopathy |
| Q36909237 | Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy. |
| Q38936784 | DDiT4L promotes autophagy and inhibits pathological cardiac hypertrophy in response to stress. |
| Q28267272 | Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation |
| Q36184207 | Diet and aging |
| Q41986027 | Differential contribution of insulin and amino acids to the mTORC1-autophagy pathway in the liver and muscle |
| Q34216750 | Drosophila, genetic screens, and cardiac function |
| Q33792524 | Effect of lithium on ventricular remodelling in infarcted rats via the Akt/mTOR signalling pathways |
| Q57300947 | Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases |
| Q47252604 | Emerging roles of RNA-binding proteins in diabetes and their therapeutic potential in diabetic complications. |
| Q83226379 | Endothelial EphB4 maintains vascular integrity and transport function in adult heart |
| Q35663684 | Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia |
| Q34307302 | Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation |
| Q92826281 | For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors |
| Q38781072 | Fuel availability and fate in cardiac metabolism: A tale of two substrates |
| Q90725026 | GRP78 (Glucose-Regulated Protein of 78 kDa) Promotes Cardiomyocyte Growth Through Activation of GATA4 (GATA-Binding Protein 4) |
| Q30417331 | Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart |
| Q38294246 | Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish |
| Q41627722 | High-density lipoprotein protects cardiomyocytes from oxidative stress via the PI3K/mTOR signaling pathway |
| Q34836259 | IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. |
| Q40630534 | Impact of caloric restriction on myocardial ischaemia/reperfusion injury and new therapeutic options to mimic its effects |
| Q104111362 | Inhibiting the Pkm2/b-catenin axis drives in vivo replication of adult cardiomyocytes following experimental MI |
| Q36812158 | Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression |
| Q45012762 | Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling |
| Q39180915 | Insights for Oxidative Stress and mTOR Signaling in Myocardial Ischemia/Reperfusion Injury under Diabetes. |
| Q39284965 | Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons. |
| Q30377910 | Insulin Signaling and Heart Failure. |
| Q42818693 | Insulin receptor substrate signaling suppresses neonatal autophagy in the heart. |
| Q38261284 | Insulin regulation of myocardial autophagy. |
| Q37829489 | LKB1 loss of function studied in vivo |
| Q53516074 | Links between mTOR and the immunoproteasome: Therapeutic targets for cardiac hypertrophy? |
| Q92398990 | Loss of SRSF3 in Cardiomyocytes Leads to Decapping of Contraction-Related mRNAs and Severe Systolic Dysfunction |
| Q36171264 | Loss of long-chain acyl-CoA synthetase isoform 1 impairs cardiac autophagy and mitochondrial structure through mechanistic target of rapamycin complex 1 activation. |
| Q50435398 | MTOR controls genesis and autophagy of GABAergic interneurons during brain development |
| Q28593301 | Mammalian target of rapamycin is essential for cardiomyocyte survival and heart development in mice |
| Q37715817 | Mammalian target of rapamycin signaling in cardiac physiology and disease. |
| Q89823740 | Mechanical Regulation of Protein Translation in the Cardiovascular System |
| Q34450669 | Mechanical stimulation induces mTOR signaling via an ERK-independent mechanism: implications for a direct activation of mTOR by phosphatidic acid |
| Q63131766 | Mechanisms of physiological and pathological cardiac hypertrophy |
| Q27320013 | Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth |
| Q34039918 | Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage |
| Q39232032 | Metabolism in cardiomyopathy: every substrate matters |
| Q34473676 | MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. |
| Q35579292 | MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis |
| Q27006868 | Molecular basis of physiological heart growth: fundamental concepts and new players |
| Q27009396 | Multifaceted role of insulin-like growth factors and mammalian target of rapamycin in skeletal muscle |
| Q43232684 | NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFκB signaling pathways |
| Q53193638 | Neuregulin-1β promotes glucose uptake via PI3K/Akt in neonatal rat cardiomyocytes. |
| Q48506350 | New Insights Into the Role of mTOR Signaling in the Cardiovascular System. |
| Q35243945 | New insights into insulin resistance in the diabetic heart |
| Q92704203 | Novel Role for Pleckstrin Homology-Like Domain Family A, Member 3 in the Regulation of Pathological Cardiac Hypertrophy |
| Q47136381 | Novel obscurins mediate cardiomyocyte adhesion and size via the PI3K/AKT/mTOR signaling pathway |
| Q28588831 | Nprl3 is required for normal development of the cardiovascular system |
| Q26800197 | Ongoing controversies surrounding cardiac remodeling: is it black and white-or rather fifty shades of gray? |
| Q42067604 | Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction. |
| Q36432388 | Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade |
| Q91284093 | PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress |
| Q34429082 | PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection |
| Q36025665 | PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? |
| Q92008008 | Pathway analysis with genome-wide association study (GWAS) data detected the association of atrial fibrillation with the mTOR signaling pathway |
| Q36972415 | Pharmacological Strategies to Retard Cardiovascular Aging |
| Q37883418 | Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure |
| Q33602622 | Phosphoinositide-dependent kinase 1 and mTORC2 synergistically maintain postnatal heart growth and heart function in mice |
| Q38854987 | Physiological and pathological cardiac hypertrophy. |
| Q41628153 | Prenatal Mechanistic Target of Rapamycin Complex 1 (m TORC1) Inhibition by Rapamycin Treatment of Pregnant Mice Causes Intrauterine Growth Restriction and Alters Postnatal Cardiac Growth, Morphology, and Function. |
| Q92849644 | Pressure overload inhibits glucocorticoid receptor transcriptional activity in cardiomyocytes and promotes pathological cardiac hypertrophy |
| Q38497014 | Proteotoxicity and cardiac dysfunction |
| Q33908036 | Rag GTPases are cardioprotective by regulating lysosomal function. |
| Q36392865 | Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway. |
| Q37619336 | Rapamycin treatment of healthy pigs subjected to acute myocardial ischemia-reperfusion injury attenuates cardiac functions and increases myocardial necrosis. |
| Q37999634 | Regulation of autophagy by metabolic and stress signaling pathways in the heart |
| Q37054943 | Regulation of fatty acid metabolism by mTOR in adult murine hearts occurs independently of changes in PGC-1α |
| Q34328828 | Rheb (Ras homologue enriched in brain)-dependent mammalian target of rapamycin complex 1 (mTORC1) activation becomes indispensable for cardiac hypertrophic growth after early postnatal period |
| Q41820920 | Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome. |
| Q87666167 | Role of Everolimus on Cardiac Functions in Kidney Transplant Recipients |
| Q39506406 | Saffron (Crocus sativus) pretreatment confers cardioprotection against ischemia-reperfusion injuries in isolated rabbit heart |
| Q34117251 | Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1. |
| Q27015640 | Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin |
| Q91430120 | Signalling protein protects the heart muscle from pressure-related stress |
| Q34627013 | Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin |
| Q61801386 | Snapshot: Implications for mTOR in Aging-related Ischemia/Reperfusion Injury |
| Q99629087 | Substrate metabolism regulated by Sestrin2-mTORC1 alleviates pressure overload-induced cardiac hypertrophy in aged heart |
| Q29568312 | Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway |
| Q93005204 | TIP30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation |
| Q42562973 | Target of rapamcyin (TOR)-based therapeutics for cardiomyopathy: insights from zebrafish genetics |
| Q38030250 | Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies |
| Q93246442 | Targeting Autophagy in Aging and Aging-Related Cardiovascular Diseases |
| Q26864639 | Targeting disease through novel pathways of apoptosis and autophagy |
| Q93139745 | Targeting mTOR suppressed colon cancer growth through 4EBP1/eIF4E/PUMA pathway |
| Q36413143 | Targets, trafficking, and timing of cardiac autophagy |
| Q36979192 | Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation |
| Q36227198 | The Akt-mTOR axis is a pivotal regulator of eccentric hypertrophy during volume overload |
| Q64256257 | The Cutting Edge: The Role of mTOR Signaling in Laminopathies |
| Q35936057 | The antioxidant compound tert-butylhydroquinone activates Akt in myocardium, suppresses apoptosis and ameliorates pressure overload-induced cardiac dysfunction |
| Q39256900 | The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus |
| Q33437313 | The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study |
| Q36597976 | The programming of cardiac hypertrophy in the offspring by maternal obesity is associated with hyperinsulinemia, AKT, ERK, and mTOR activation |
| Q26996481 | The two faces of miR-29 |
| Q36913719 | Therapeutic targeting of autophagy in cardiovascular disease |
| Q26830282 | Therapeutic targeting of autophagy: potential and concerns in treating cardiovascular disease |
| Q47633679 | Thioredoxin-1 maintains mechanistic target of rapamycin (mTOR) function during oxidative stress in cardiomyocytes. |
| Q90480931 | Thioredoxin-1 maintains mitochondrial function via mTOR signaling in the heart |
| Q34969926 | Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC. |
| Q30833466 | Titin-truncating variants affect heart function in disease cohorts and the general population. |
| Q28571523 | Transcription coactivator Eya2 is a critical regulator of physiological hypertrophy |
| Q90269368 | Translating Translation to Mechanisms of Cardiac Hypertrophy |
| Q51249206 | Unacylated ghrelin analog prevents myocardial reperfusion injury independently of permeability transition pore. |
| Q37952798 | Unmasking the janus faces of autophagy in obesity-associated insulin resistance and cardiac dysfunction |
| Q37644376 | VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. |
| Q36465550 | Wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern β-amyloid apoptotic injury of microglia |
| Q35972916 | mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy |
| Q90400154 | mTOR as a Marker of Exercise and Fatigue in Octopus vulgaris Arm |
| Q91973686 | mTOR as a central regulator of lifespan and aging |
| Q34426387 | mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy |
| Q53110486 | mTOR inactivation in myocardium from infant mice rapidly leads to dilated cardiomyopathy due to translation defects and p53/JNK-mediated apoptosis. |
| Q34999217 | mTOR regulates brain morphogenesis by mediating GSK3 signaling |
| Q38056232 | mTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases |
| Q90185072 | mTORC1 Deficiency Modifies Volume Homeostatic Responses to Dietary Sodium in a Sex-Specific Manner |
| Q40182849 | mTORC2 regulates cardiac response to stress by inhibiting MST1. |
Search more.